Form 8-K - Current report:
SEC Accession No. 0001213900-25-062805
Filing Date
2025-07-10
Accepted
2025-07-10 16:30:31
Documents
13
Period of Report
2025-07-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0248611-8k_silo.htm   iXBRL 8-K 27611
2 TERMINATION, COMMERCIAL EVALUATION LICENSE, AND OPTION AGREEMENT, DATED JULY 8, ea024861101ex10-1_silo.htm EX-10.1 82652
  Complete submission text file 0001213900-25-062805.txt   293350

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE silo-20250708.xsd EX-101.SCH 3020
4 XBRL LABEL FILE silo-20250708_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE silo-20250708_pre.xml EX-101.PRE 22362
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0248611-8k_silo_htm.xml XML 3566
Mailing Address 677 N. WASHINGTON BLVD SARASOTA FL 34236
Business Address 677 N. WASHINGTON BLVD SARASOTA FL 34236 (718) 400-9031
Silo Pharma, Inc. (Filer) CIK: 0001514183 (see all company filings)

EIN.: 462137136 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41512 | Film No.: 251116615
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)